New Guidance on Using High-Efficacy DMTs in Multiple Sclerosis

High-efficacy therapies for multiple sclerosis have improved disease outcomes for many patients, but physicians are uncertain when to use them.

Related Keywords

Sweden ,Japan ,Canada ,Denmark ,Toronto ,Ontario ,Barcelona ,Comunidad Autonoma De Cataluna ,Spain ,Japanese ,Roche Genentech ,Merck Serono ,Gavin Giovannoni ,Patricia Coyle ,Dalia Rotstein ,Xavier Montalban ,Glaxosmithkline ,Genentech ,European Academy Of Neurology ,Hebron University Hospital ,Jazz Pharmaceuticals ,Merck Co ,Sclerosis Centre Of Catalonia At Vall ,Novartis ,University Of Toronto ,Sanofi Aventis ,Queen Mary University Of London ,Biogen Idec ,Serono ,Research In Multiple Sclerosis ,European Committee For Treatment ,European Committee ,Multiple Sclerosis ,Care Center ,Stony Brook ,European Academy ,Expanded Disability Status Scale ,Multiple Sclerosis Centre ,Induction Therapy ,Queen Mary University ,Roche Canada ,Atara Bio ,Japanese Tobacco ,Multiple Sclerosis Ms ,Us ,Disease Modifying Therapy ,Mt ,Neoadjuvant ,Disability ,Magnetic Resonance Imaging Mri ,Magnetic Resonance Imaging ,Ri ,Maging Magnetic Resonance ,Poverty ,Inancial Hardship ,Social Determinants Of Health ,Social Issues ,Autoimmune Disease ,Biologic Therapy ,Immunomodulator ,Lenalidomide ,Secondary Progressive Multiple Sclerosis ,Pms ,Aggression ,Anxiet ,